human herpesvirus 2

Summary

Summary: A species of SIMPLEXVIRUS associated with genital infections (HERPES GENITALIS). It is transmitted by sexual intercourse and close personal contact.

Top Publications

  1. ncbi Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor
    R J Geraghty
    Department of Microbiology Immunology, Northwestern University Medical School, Chicago, IL 60611, USA
    Science 280:1618-20. 1998
  2. pmc Effect of herpes simplex suppression on incidence of HIV among women in Tanzania
    Deborah Watson-Jones
    London School of Hygiene and Tropical Medicine, London
    N Engl J Med 358:1560-71. 2008
  3. ncbi Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus
    Nicolas Nagot
    Centre Muraz, Bobo Dioulasso, Burkina Faso
    N Engl J Med 356:790-9. 2007
  4. ncbi Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons
    A Wald
    Department of Medicine, University of Washington, Seattle 98122, USA
    N Engl J Med 342:844-50. 2000
  5. pmc Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    J Infect Dis 198:1804-8. 2008
  6. ncbi Glycoprotein-D-adjuvant vaccine to prevent genital herpes
    Lawrence R Stanberry
    Department of Pediatrics and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston 77555 0351, USA
    N Engl J Med 347:1652-61. 2002
  7. pmc Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation
    Jia Zhu
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA
    J Exp Med 204:595-603. 2007
  8. ncbi Herpes simplex: insights on pathogenesis and possible vaccines
    David M Koelle
    Department of Medicine, University of Washington, Seattle, Washington, USA
    Annu Rev Med 59:381-95. 2008
  9. pmc Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells
    Jennifer Lund
    Section of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Exp Med 198:513-20. 2003
  10. ncbi Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial
    Richard A Zuckerman
    Section of Infectious Disease and International Health, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
    J Infect Dis 196:1500-8. 2007

Detail Information

Publications283 found, 100 shown here

  1. ncbi Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor
    R J Geraghty
    Department of Microbiology Immunology, Northwestern University Medical School, Chicago, IL 60611, USA
    Science 280:1618-20. 1998
    ..HveC was expressed in human cells of epithelial and neuronal origin; it is the prime candidate for the coreceptor that allows both HSV-1 and HSV-2 to infect epithelial cells on mucosal surfaces and spread to cells of the nervous system...
  2. pmc Effect of herpes simplex suppression on incidence of HIV among women in Tanzania
    Deborah Watson-Jones
    London School of Hygiene and Tropical Medicine, London
    N Engl J Med 358:1560-71. 2008
    ..This study tested the hypothesis that HSV-2 suppressive therapy reduces the risk of HIV acquisition...
  3. ncbi Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus
    Nicolas Nagot
    Centre Muraz, Bobo Dioulasso, Burkina Faso
    N Engl J Med 356:790-9. 2007
    ..Epidemiologic data suggest that infection with herpes simplex virus type 2 (HSV-2) is associated with increased genital shedding of human immunodeficiency virus type 1 (HIV-1) RNA and HIV-1 transmissibility...
  4. ncbi Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons
    A Wald
    Department of Medicine, University of Washington, Seattle 98122, USA
    N Engl J Med 342:844-50. 2000
    ..Historically, it has been assumed that these persons have less frequent viral reactivation than those with symptomatic infection...
  5. pmc Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    J Infect Dis 198:1804-8. 2008
    ..001]), as was cervical HIV-1 level (-0.35 log10 copies/swab, a 55% decrease [P < .001]). Suppressive HSV-2 therapy has the potential to reduce HIV-1 infectiousness and slow HIV-1 disease progression...
  6. ncbi Glycoprotein-D-adjuvant vaccine to prevent genital herpes
    Lawrence R Stanberry
    Department of Pediatrics and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston 77555 0351, USA
    N Engl J Med 347:1652-61. 2002
    ..An effective prophylactic vaccine would help control the spread of genital herpes...
  7. pmc Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation
    Jia Zhu
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA
    J Exp Med 204:595-603. 2007
    ..These findings indicate that the frequency and clinical course of HSV-2 reactivation in humans is influenced by virus-specific CD8(+) T cells that persist in peripheral mucosa and genital skin after resolution of herpes lesions...
  8. ncbi Herpes simplex: insights on pathogenesis and possible vaccines
    David M Koelle
    Department of Medicine, University of Washington, Seattle, Washington, USA
    Annu Rev Med 59:381-95. 2008
    ....
  9. pmc Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells
    Jennifer Lund
    Section of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Exp Med 198:513-20. 2003
    ..Therefore, these results demonstrate a novel mechanism whereby the genomic DNA of a virus can engage TLR9 and result in the secretion of IFN-alpha by pDCs...
  10. ncbi Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial
    Richard A Zuckerman
    Section of Infectious Disease and International Health, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
    J Infect Dis 196:1500-8. 2007
    ..We studied HIV-1 levels during HSV suppression in coinfected persons in a placebo-controlled crossover trial...
  11. ncbi Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India
    Steven J Reynolds
    Division of Infectious Diseases, School of Medicine, Baltimore, Maryland 21205, USA
    J Infect Dis 187:1513-21. 2003
    ..81 for recent incident HSV-2. Recent incident HSV-2 infection was associated with the highest risk of HIV-1 in this study, which suggests that prevention of HSV-2 infection may reduce the risk of HIV-1 acquisition...
  12. pmc Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs
    Yo Hoshino
    Medical Virology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland 20892, USA
    J Virol 79:410-8. 2005
    ..Given its efficacy, its defectiveness for latency, and its ability to induce rapid, virus-specific CD8(+)-T-cell responses, the dl5-29 vaccine may be a good candidate for early-phase human trials...
  13. ncbi Synergistic copathogens--HIV-1 and HSV-2
    Lawrence Corey
    N Engl J Med 356:854-6. 2007
  14. ncbi Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States
    David N Fisman
    City of Hamilton Social and Public Health Services Department, McMaster University, Hamilton, Ontario, Canada
    Sex Transm Dis 29:608-22. 2002
    ....
  15. pmc Herpes simplex virus triggers activation of calcium-signaling pathways
    Natalia Cheshenko
    Deparment of Pediatrics and Microbiology, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Cell Biol 163:283-93. 2003
    ..Defining the pathway of viral invasion may lead to new targets for anti-viral therapy...
  16. ncbi Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora
    Thomas L Cherpes
    Department of Medicine, Division of Infectious Disease, Magee Womens Research Institute, 204 Craft Avenue, Pittsburgh, PA 15213, USA
    Sex Transm Dis 30:405-10. 2003
    ..Herpes simplex virus type 2 (HSV-2), the primary cause of genital herpes, is one of the most prevalent sexually transmitted diseases worldwide. Epidemiologic serosurveys suggest that infections occur more frequently in women than in men...
  17. pmc Risk factors for herpes simplex virus type 2 and HIV among women at high risk in northwestern Tanzania: preparing for an HSV-2 intervention trial
    Deborah Watson-Jones
    London School of Hygiene and Tropical Medicine, London, England
    J Acquir Immune Defic Syndr 46:631-42. 2007
    ..To determine prevalence of and risk factors for herpes simplex virus type 2 (HSV-2) and HIV among women being screened for a randomized, controlled trial of HSV suppressive therapy in northwestern Tanzania...
  18. ncbi PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial
    Marla J Keller
    Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Infect Dis 193:27-35. 2006
    ..This study was designed to determine the antiviral activity in cervicovaginal lavage (CVL) samples collected after intravaginal application of 0.5% PRO 2000 gel (Indevus)...
  19. ncbi A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology
    Thomas L Cherpes
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Sex Transm Dis 35:78-83. 2008
    ..The etiology of bacterial vaginosis (BV) is poorly understood, but better definition of the risk factors associated with its acquisition should improve our understanding of this complex disease entity...
  20. pmc Simultaneous PCR detection of Haemophilus ducreyi, Treponema pallidum, and herpes simplex virus types 1 and 2 from genital ulcers
    K A Orle
    Roche Molecular Systems, Alameda, California 94501, USA
    J Clin Microbiol 34:49-54. 1996
    ..8, 74.2, and 81%, respectively. These results indicate that the M-PCR assay is more sensitive than standard diagnostic tests for the detection of HSV, H. ducreyi, and T. pallidum from genital ulcers...
  21. pmc Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes
    Nancy Hosken
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98109, USA
    J Virol 80:5509-15. 2006
    ..Whether this variability in the CD8(+) T-cell response within individuals is associated with the frequency of viral reactivation warrants further study...
  22. ncbi Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States
    Fujie Xu
    Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    JAMA 296:964-73. 2006
    ..Preexisting HSV-1 antibodies can alleviate clinical manifestations of subsequently acquired HSV-2. Furthermore, HSV-1 has become an important cause of genital herpes in some developed countries...
  23. ncbi A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge
    X Zhang
    Laboratory of Cellular and Molecular Immunology, The Gavin S Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA, USA
    Mucosal Immunol 2:129-43. 2009
    ..IVAG immunization with self-adjuvanting lipid-tailed peptides appears to be a novel mucosal vaccine approach, which has attractive practical and immunological features...
  24. ncbi Neonatal herpes simplex virus infection
    Richard Whitley
    University of Alabama at Birmingham, Birmingham, Alabama 35233, USA
    Curr Opin Infect Dis 17:243-6. 2004
    ..This review considers recent advances that impact on disease management...
  25. ncbi The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics
    Lawrence Corey
    Department of Medicine, University of Washington Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Acquir Immune Defic Syndr 35:435-45. 2004
    ....
  26. pmc Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes
    D M Koelle
    Department of Medicine, University of Washington, Seattle, Washington 98195, USA
    J Clin Invest 101:1500-8. 1998
    ..The phenotypes of cells with HSV-specific cytotoxic responses varied between patients, having CD4+ and CD8+ components. Immunotherapeutic approaches to HSV should be directed at improving in vivo cytolytic activity to HSV...
  27. pmc Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa
    Joëlle Sobngwi-Tambekou
    INSERM U687, Villejuif, France
    J Infect Dis 199:958-64. 2009
    ....
  28. pmc A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2
    K J Looker
    Department of Infectious Disease Epidemiology, Imperial College Faculty of Medicine, St Mary s Campus, Norfolk Place, London W2 1PG, UK
    Sex Transm Infect 81:103-7. 2005
    ..To explore epidemiological evidence about the interaction of herpes simplex virus (HSV) 1 and HSV-2 infections...
  29. ncbi Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study
    John O'Loughlin
    Royal Adelaide Hospital, Adelaide, Australia
    Sex Transm Dis 37:100-4. 2010
    ..To evaluate safety, tolerability and systemic pharmacokinetics of escalating doses of SPL7013 Gel in healthy women...
  30. pmc In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa
    Melissa M Linehan
    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    J Virol 78:2530-6. 2004
    ..Together, these results suggest the importance of nectin-1 in mediating viral entry for both HSV-1 and HSV-2 in the genital mucosa in female hosts...
  31. ncbi Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection
    Minnie John
    Department of Pediatrics, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Infect Dis 192:1731-40. 2005
    ..In contrast, all 15 mice challenged with untreated HSV-2 died. These findings are evidence that cervicovaginal secretions contribute to innate resistance to HSV-2 and identify defensins as contributors to this activity...
  32. pmc The murine homolog (Mph) of human herpesvirus entry protein B (HveB) mediates entry of pseudorabies virus but not herpes simplex virus types 1 and 2
    D Shukla
    Department of Microbiology Immunology, Northwestern University Medical School, Chicago, Illinois 60611, USA
    J Virol 73:4493-7. 1999
    ..By analogy with HSV-1, envelope-associated PRV gD probably also interacts directly with mHveB during viral entry...
  33. pmc Herpes simplex virus type 2 (HSV-2) establishes latent infection in a different population of ganglionic neurons than HSV-1: role of latency-associated transcripts
    Todd P Margolis
    F I Proctor Foundation, University of California, San Francisco, San Francisco, CA 94143, USA
    J Virol 81:1872-8. 2007
    ....
  34. ncbi Natural history of neonatal herpes simplex virus infections in the acyclovir era
    D W Kimberlin
    Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama 35233, USA
    Pediatrics 108:223-9. 2001
    ..The objective of this study was to provide an update of neonatal HSV disease to identify means by which future improvements in the management of HSV-infected neonates can be made...
  35. pmc Clearance of herpes simplex virus type 2 by CD8+ T cells requires gamma interferon and either perforin- or Fas-mediated cytolytic mechanisms
    Melanie E Dobbs
    Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA
    J Virol 79:14546-54. 2005
    ..However, either perforin- or Fas-mediated cytolytic mechanisms were required to achieve complete clearance of HSV-2 from the genital epithelium...
  36. ncbi Seminal plasma reduces the effectiveness of topical polyanionic microbicides
    Sarju Patel
    Department of Pediatrics, Mount Sinai School of Medicine, New York, NY, USA
    J Infect Dis 196:1394-402. 2007
    ..0007, log rank test). If these findings are reflective of what occurs in humans, modifications to microbicides to ensure that they retain activity in the presence of seminal plasma are indicated...
  37. pmc Herpes simplex virus type 2: epidemiology and management options in developing countries
    G Paz-Bailey
    Global AIDS Program for Central America National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Sex Transm Infect 83:16-22. 2007
    ..Meanwhile, multifaceted interventions are required to improve recognition of genital herpes, to prevent its spread and also to prevent its potential to promote HIV transmission in developing countries...
  38. ncbi Epidemiology of herpes simplex virus type 2 infection in the developing world
    Helen Weiss
    London School of Hygiene and Tropical Medicine, London, UK
    Herpes 11:24A-35A. 2004
    ..Where possible, the aetiology of GUD should be evaluated using polymerase chain reaction (PCR), while recognizing that co-pathogens can exist in a lesion. GUD management should incorporate HIV testing and antiherpetic treatment...
  39. pmc HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men
    Richard A Zuckerman
    Section of Infectious Disease and International Health, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    AIDS 23:479-83. 2009
    ..Suppressive herpes simplex virus (HSV) therapy can decrease plasma, cervical, and rectal HIV-1 levels in HIV-1/HSV-2 co-infected persons. We evaluated the effect of HSV-2 suppression on seminal HIV-1 levels...
  40. pmc Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition
    Jia Zhu
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Nat Med 15:886-92. 2009
    ..The persistence and enrichment of HIV receptor-positive inflammatory cells in the genitalia help explain the inability of anti-HSV-2 therapy to reduce HIV acquisition...
  41. pmc N-terminal mutants of herpes simplex virus type 2 gH are transported without gL but require gL for function
    Tina M Cairns
    Department of Microbiology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Virol 81:5102-11. 2007
    ..Additional mutagenesis identified L66 and L72 as important for function. Together, our results highlight several key gH residues: R39, Y41, W42, and D44 for gH transport and L66 and L72 for gH/gL structure and function...
  42. ncbi Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention
    W E Lafferty
    Dept of Health Services, University of Washington, Seattle, WA 98195 7660, USA
    J Infect Dis 181:1454-7. 2000
    ..Genital HSV-1 may often be acquired through contact with a partner's mouth. These data suggest that seroprevalence studies based solely on HSV-2 type-specific assays underestimate overall prevalence of genital HSV infection...
  43. ncbi Epidemiology of genital herpes simplex virus infections in a community-based sample in France: results of the HERPIMAX study
    Denis Malvy
    EA 3677, Universite Bordeaux 2, France
    Sex Transm Dis 32:499-505. 2005
    ..The objective of this study was to provide information on the prevalence of herpes simplex infections in the general population in Europe...
  44. ncbi Molecular basis of the interactions between herpes simplex viruses and HIV-1
    G Palu
    Department of Histology, Microbiology and Medical Biotechnologies, Section of Microbiology and Virology, University of Padua, Via A Gabelli 63, 35121 Padua, Italy
    Herpes 8:50-5. 2001
    ....
  45. ncbi Herpes simplex virus type-2 infection in pregnancy: no risk of fetal death: results from a nested case-control study within 35,940 women
    Anne Eskild
    Section of Epidemiology, National Institute of Public Health, Oslo, Norway
    BJOG 109:1030-5. 2002
    ..presence of antibodies in first trimester; 2. appearance of antibodies (incident infection); 3. increase in antibody titre; and 4. loss of antibodies...
  46. pmc Epidemiology of recurrent genital herpes simplex virus types 1 and 2
    L Solomon
    Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Sex Transm Infect 79:456-9. 2003
    ..To describe the epidemiology of type specific recurrent genital herpes, and to compare the duration of recurrent genital lesions caused by herpes simplex virus (HSV) types 1 and 2...
  47. pmc Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment
    A Wald
    Department of Medicine, University of Washington, Seattle 98195, USA
    J Clin Invest 99:1092-7. 1997
    ..HSV-2 shedding in the genital mucosa occurs much more frequently than previously appreciated. This frequent reactivation likely plays a role in the epidemic spread of genital herpes worldwide...
  48. ncbi Role of mucosal immunity in preventing genital herpes infection
    Veronica MasCasullo
    Department of Pediatrics, Mount Sinai School of Medicine, New York, New York 10029, USA
    Viral Immunol 18:595-606. 2005
    ..Understanding how each of these components contribute to innate immunity, mechanisms of antiviral activity, and whether the virus has evolved strategies to evade their effects may lead to the development of novel vaginal microbicides...
  49. ncbi Sexually transmitted herpes simplex viruses
    Maria Karolina Jonsson
    Department of Virology, Swedish Institute for Infectious Disease Control, Microbiology and Tumour Biology Centre, Karolinska Institute, SE 171 82 Stockholm, Sweden
    Scand J Infect Dis 36:93-101. 2004
    ....
  50. ncbi Seroprevalence of herpes simplex virus types 1 and type 2 in the Frankfurt am Main area, Germany
    H F Rabenau
    Institute for Medical Virology, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
    Med Microbiol Immunol 190:153-60. 2002
    ..The same is true when investigating HSV-1 seroprevalence rates in HSV-2-seropositive or -negative individuals, retrospectively...
  51. ncbi Seroprevalence of herpes simplex virus type 1 and type 2 in selected German populations-relevance for the incidence of genital herpes
    P Wutzler
    Institute for Antiviral Chemotherapy, Friedrich Schiller University of Jena, Jena, Germany
    J Med Virol 61:201-7. 2000
    ....
  52. pmc Type specific seroprevalence of HSV-1 and HSV-2 in four geographical regions of Poland
    J S Smith
    Department of Virology, National Institute of Hygiene, Warsaw, Poland
    Sex Transm Infect 82:159-63. 2006
    ..To examine the type specific seroprevalence of herpes simplex virus (HSV) types 1 and 2 infections, stratified by age and gender, and associated risk factors for HSV-2 seropositivity in Poland...
  53. ncbi Nonoxynol-9 enhances rectal infection by herpes simplex virus in mice
    D M Phillips
    Contraception 57:341-8. 1998
    ..These findings suggest that use of N9-containing products during rectal intercourse may increase the risk of infection with HSV-2 or other sexually transmitted pathogens...
  54. pmc Impact of stepping stones on incidence of HIV and HSV-2 and sexual behaviour in rural South Africa: cluster randomised controlled trial
    Rachel Jewkes
    Gender and Health Research Unit, Medical Research Council, Private Bag X385, Pretoria 0001, South Africa
    BMJ 337:a506. 2008
    ..To assess the impact of Stepping Stones, a HIV prevention programme, on incidence of HIV and herpes simplex type 2 (HSV-2) and sexual behaviour...
  55. pmc Ethics of screening for asymptomatic herpes virus type 2 infection
    Ingela Krantz
    Department of Public Health and Clinical Medicine, Epidemiology, Umea University, Sweden
    BMJ 329:618-21. 2004
  56. pmc Truncation of herpes simplex virus type 2 glycoprotein B increases its cell surface expression and activity in cell-cell fusion, but these properties are unrelated
    Zhenghong Fan
    Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71130, USA
    J Virol 76:9271-83. 2002
    ..Therefore, syncytial mutations in the cytoplasmic tail of gB-2 do not act by increasing cell surface levels of the protein...
  57. pmc The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection
    S L Rosenthal
    Department of Pediatrics, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA
    Sex Transm Infect 82:154-7; discussion 157-8. 2006
    ..To evaluate the impact of a positive herpes simplex virus type 2 (HSV-2) serological test on psychosocial functioning among people with no known history of genital herpes...
  58. pmc Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey
    A L Cunningham
    Sexually Transmitted Infections Research Centre and University of Sydney, Marian Villa, Westmead Hospital, Westmead, NSW 2145, Australia
    Sex Transm Infect 82:164-8. 2006
    ..The only nationwide seroprevalence studies have been conducted in the United States...
  59. pmc Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults
    Karen E Mark
    Department of Medicine, University of Washington, Seattle, Washington 98122, USA
    J Infect Dis 198:1141-9. 2008
    ..Recent in situ data show the localization of HSV-specific CD8(+) T cells at the dermal epidermal junction next to peripheral sensory nerve endings, suggesting that viral reactivation may occur more frequently than previously appreciated...
  60. pmc Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor
    David M Koelle
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 100:12899-904. 2003
    ..We conclude that among circulating cells expressing a homing-associated receptor, during chronic herpes type 2 infection, the CD8 T cell response becomes quite focused despite the presence of many potential antigenic peptides...
  61. ncbi Comparison of Light-Cycler PCR, enzyme immunoassay, and tissue culture for detection of herpes simplex virus
    M Koenig
    Microbiology Division, Department of Pathology and Area Laboratory Services, Landstuhl Regional Medical Center, Landstuhl, Germany
    Diagn Microbiol Infect Dis 40:107-10. 2001
    ..The amplified product may be typed without additional tests. The LightCycler PCR method provides a rapid method for HSV detection that correlates well with established tests...
  62. ncbi Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial
    Karen E Mark
    Department of Medicine, University of Washington, Seattle, WA 98104, USA
    J Infect Dis 195:1324-31. 2007
    ..In animal models, induction of Th1-specific responses modifies experimental herpes simplex virus (HSV) infection...
  63. ncbi Herpes simplex inhibits the capacity of lymphoblastoid B cell lines to stimulate CD4+ T cells
    S Barcy
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA
    J Immunol 166:6242-9. 2001
    ..These data indicate a novel immune evasion strategy by HSV-1 in which Ag-processing cells that become infected by HSV-1 are inhibited in their ability to induce subsequent CD4(+) T cell activation...
  64. ncbi Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling
    Sami L Gottlieb
    Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Infect Dis 190:1059-67. 2004
    ..controls). The possible benefit of RRC in preventing acquisition of HSV-2 infection offers encouragement that interventions more specifically tailored to genital herpes may be useful and should be an important focus of future studies...
  65. ncbi Human herpesvirus 8 and human herpesvirus 2 infections in prison population
    L Sarmati
    Clinic of Infectious Diseases, University of Tor Vergata, Rome, Italy
    J Med Virol 79:167-73. 2007
    ..004). A relatively high seroprevalence of HHV-8 and HSV-2 among Italian prison inmates was found. The association of HHV-8 and HSV-2 infections suggest sexual transmission of these viruses among Italian prison inmates...
  66. ncbi Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection
    Anna Wald
    Department of Medicine, University of Washington, Virology Research Clinic, Seattle, WA, USA
    Clin Infect Dis 35:S173-82. 2002
    ..Potential settings for use of these tests include sexually transmitted disease clinics, prenatal clinics, and clinics that care for patients with human immunodeficiency virus. Patient interest in HSV serological tests appears high...
  67. ncbi Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda
    David Serwadda
    Institute of Public Health, Makerere University, Kampala, Uganda
    J Infect Dis 188:1492-7. 2003
    ..HIV load is increased in HSV-2-positive subjects who seroconverted, suggesting a role for treatment of HSV-2 infection in HSV-2-seropositive, dually infected individuals...
  68. pmc Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003
    T Tran
    Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, 3051Victoria, Australia
    Sex Transm Infect 80:277-9. 2004
    ..To investigate changes in the proportions of patients infected with genital herpes simplex virus (HSV) types 1 and 2 from 1980 to 2003 in Melbourne, Australia...
  69. pmc Seroprevalence of HSV-1 and HSV-2 infection in the general French population
    J E Malkin
    Service de Pathologie Infectieuse et Tropicale, Centre Médicale de l Institut Pasteur, Paris, France
    Sex Transm Infect 78:201-3. 2002
    ..We present the results of HERPIMAX, the first epidemiological inquiry on HSV prevalence in the general French population...
  70. ncbi Herpes simplex virus type 2 transmission: risk factors and virus shedding
    Anna Wald
    University of Washington, Virology Research Clinic, Seattle, WA 98122, USA
    Herpes 11:130A-137A. 2004
    ..Clinical history is a poor predictor of HSV-2 infection and type-specific serological testing is recommended to detect HSV-2 seropositivity...
  71. pmc The seroepidemiology of herpes simplex virus type 1 and 2 in Europe
    R G Pebody
    Immunisation Department, Communicable Disease Surveillance Centre, London, UK
    Sex Transm Infect 80:185-91. 2004
    ..To describe the seroepidemiology of herpes simplex virus (HSV) types 1 and 2 in the general populations of eight European countries to better understand recent reported changes in disease epidemiology...
  72. ncbi Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses
    Edwin Gong
    Viridae Clinical Sciences Inc, Vancouver, BC, Canada
    Antiviral Res 68:139-46. 2005
    ..The 50% cytotoxic concentrations (CC(50)) in all cases were greater than 10,000 microg/ml. Our data indicate that SPL7013 is a promising candidate for development as a vaginal microbicide and a therapeutic agent...
  73. ncbi Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization
    R A Maguire
    Population Council, New York, New York 10021, USA
    Sex Transm Dis 28:259-65. 2001
    ..CONCLUSION: Evaluating formulations under the same testing conditions can help to distinguish among potential formulations that are likely to show promise as safe and effective microbicides...
  74. ncbi Management of herpes simplex virus type 2 infection in HIV type 1-infected persons
    Lara B Strick
    Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98104, USA
    Clin Infect Dis 43:347-56. 2006
    ..Studies to quantify the potential clinical and public health benefits of treating individuals who have HIV-1 and HSV-2 coinfection with anti-HSV therapy are underway...
  75. pmc Association between bacterial vaginosis and Herpes simplex virus type-2 infection: implications for HIV acquisition studies
    Nicolas Nagot
    London School of Hygiene and Tropical Medicine, ITD CRU, London, UK
    Sex Transm Infect 83:365-8. 2007
    ..Recent research suggests an association between BV and HSV-2 acquisition, but the converse has not been studied. Here, we investigate whether an association exists between BV and HSV-2 infection..
  76. ncbi Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant
    Zane A Brown
    Department of Obstetrics and Gynecology, University of Washington, Box 356460, Seattle, WA 98195 6460, USA
    JAMA 289:203-9. 2003
    ..Furthermore, no data exist on whether cesarean delivery, the standard of care for women with genital herpes lesions at the time of delivery, reduces HSV transmission...
  77. ncbi Association between cervical shedding of herpes simplex virus and HIV-1
    R Scott McClelland
    International AIDS Research and Training Program, Department of Medicine, University of Washington, Box 359909, 325 9th Avenue, Seattle, WA 98104, USA
    AIDS 16:2425-30. 2002
    ..To investigate the association between the cervical shedding of herpes simplex virus (HSV) and HIV-1...
  78. ncbi Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression
    Timothy Schacker
    Department of Medicine, University of Minnesota, Minneapolis, 55455, USA
    J Infect Dis 186:1718-25. 2002
    ..These data indicate that frequent mucosal HSV reactivation influences HIV replication in vivo and daily HSV suppression may be important in the management of HSV-positive/HIV-positive persons...
  79. ncbi The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania
    Saidi H Kapiga
    Department of Population and International Health, Harvard School of Public Health, Boston, MA 02115, USA
    J Infect Dis 195:1260-9. 2007
    ....
  80. ncbi Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge
    L A Morrison
    Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Missouri 63104, USA
    Virology 243:178-87. 1998
    ..These results suggest that mucosal immunization may complement protective immunity against HSV-2 genital infection generated by parenteral immunization with replication-defective mutant virus...
  81. pmc Herpes simplex virus type 2 induces rapid cell death and functional impairment of murine dendritic cells in vitro
    C A Jones
    Herpesvirus Research Unit, Department of Immunology and Infectious Diseases, The University of Sydney, Parkville, New South Wales, Australia
    J Virol 77:11139-49. 2003
    ..Thus, there are marked differences in the levels of HSV-induced cytolysis in DC according to the HSV serotype, although HSV-2 displays immunomodulatory effects on the DC immunophenotype and function similar to those of HSV-1...
  82. ncbi Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review
    Jennifer S Smith
    International Agency for Research on Cancer IARC, Unit of Field and Intervention Studies, 69372 Lyon, France
    J Infect Dis 186:S3-28. 2002
    ..HSV-1 infection is acquired during childhood and adolescence and is markedly more widespread than HSV-2 infection. Further studies are needed in many geographic areas...
  83. ncbi Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities
    Hinda J Ahmed
    Department of Medical Microbiology and Immunology, University of Goteborg, Goteborg, Sweden
    Sex Transm Dis 30:114-9. 2003
    ..GUD increases the risk of infection with HIV. However, the association between specific GUD infections and HIV infection has not been fully investigated...
  84. pmc Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus
    Norifumi Iijima
    Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Exp Med 205:3041-52. 2008
    ..Thus, these results revealed a distinct mechanism by which memory Th1 cells mediate noncytolytic IFN-gamma-dependent antiviral protection after recognition of processed viral antigens by local DCs and B cells...
  85. ncbi Genital herpes
    Rachna Gupta
    Department of Medicine, University of Washington, Seattle, USA
    Lancet 370:2127-37. 2007
    ..Antiviral treatment of the infected partners and condom use reduce the risk of sexual transmission of HSV-2...
  86. pmc Male circumcision for the prevention of HSV-2 and HPV infections and syphilis
    Aaron A R Tobian
    Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    N Engl J Med 360:1298-309. 2009
    ..We assessed the efficacy of male circumcision for the prevention of herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) infections and syphilis in HIV-negative adolescent boys and men...
  87. ncbi Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice
    A M Harandi
    Departments of Medical Microbiology and Immunology and Clinical Virology, , Guldhedsgatan 10A, , Sweden
    J Gen Virol 82:845-53. 2001
    ....
  88. ncbi Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization
    Thomas L Cherpes
    Department of Medicine, Division of Infectious Disease, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Clin Infect Dis 40:1422-8. 2005
    ..We investigated the effects of vaginal coinfections and hormonal contraceptive use on genital tract shedding of HSV-2 in women...
  89. ncbi Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students
    Craig M Roberts
    University Health Services, University of Wisconsin Madison, Madison, Wisconsin 53726, USA
    Sex Transm Dis 30:797-800. 2003
    ..HSV-1 accounted for 78% of all genital isolates in this population by 2001, compared with 31% of isolates in 1993...
  90. pmc The genome sequence of herpes simplex virus type 2
    A Dolan
    MRC Virology Unit, Institute of Virology, Glasgow, United Kingdom
    J Virol 72:2010-21. 1998
    ..J. Davison, A. Dolan, M. C. Frame, D. McNab, L. J. Perry, J. E. Scott, and P. Taylor, J. Gen. Virol. 69:1531-1574, 1988). No compelling evidence for the existence of any additional protein-coding genes in HSV-2 was identified...
  91. ncbi Nitric oxide and HSV vaginal infection in BALB/c mice
    Fabian Benencia
    Laboratory of Immunochemistry, Department of Biological Chemistry, Faculty of Sciences, University of Buenos Aires, Pabellon II, Piso 4, Ciudad Universitaria, 1428 Buenos Aires, Argentina
    Virology 309:75-84. 2003
    ..Finally, RT-PCR analysis showed increased expression of the chemokines MIP-2 and RANTES in vaginal tissue and inguinal lymph nodes of these animals...
  92. ncbi Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread
    Natalia Cheshenko
    Department of Pediatrics and Microbiology, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1657, New York, NY 10029, USA
    J Gen Virol 83:2247-55. 2002
    ..Together these studies demonstrate that gB-2 plays a key role in mediating HSV-2 attachment and is required for entry and cell-to-cell spread. This glycoprotein is an important target for development of novel antiviral drugs...
  93. doi Reassessing the hypothesis on STI control for HIV prevention
    Ronald H Gray
    Johns Hopkins University, Baltimore, MD 21205, USA
    Lancet 371:2064-5. 2008
  94. ncbi Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10)
    L Aurelian
    Virology Immunology Laboratories, Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore 21201, USA
    Vaccine 17:1951-63. 1999
    ..i. ICP10 deltaPK immunized animals developed HSV-specific humoral and T-cell responses and evidenced absolute protection from HSV-2 infection and virus-induced disease...
  95. ncbi [Seroprevalence of herpes simplex virus type 2 (HSV-2) infection in two clinics for sexually transmitted diseases in Santiago, Chile]
    Maria Jose Martinez
    Programa de Virología ICBM, Facultad de Medicina, Universidad de Chile, Chile
    Rev Med Chil 133:302-6. 2005
    ..Genital herpes, a sexually transmitted disease caused by herpes simplex virus type 2 (HSV-2), is found in 3.8% of all sexually transmitted diseases (STD) in Chile...
  96. ncbi Psychosocial impact of type-specific herpes simplex serological testing on asymptomatic sexual health clinic attendees
    A Smith
    Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne, Australia
    Int J STD AIDS 11:15-20. 2000
    ..While supportive of the value of HSV-2 testing, these findings require replication in larger samples and different populations...
  97. pmc Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production
    Navkiran Gill
    Centre for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University Health Sciences Centre, Hamilton L8N 3Z5, Ontario, Canada
    J Virol 80:9943-50. 2006
    ..Results from these in vivo studies clearly suggest a strong correlation between IFN-beta production and innate antiviral immunity against HSV-2...
  98. pmc Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection
    Melissa M Herbst-Kralovetz
    Sealy Center for Vaccine Development, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555 0436, USA
    J Virol 80:9988-97. 2006
    ....
  99. ncbi An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2)
    William A Rose
    Department of Pediatrics and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA
    Int J Antimicrob Agents 32:262-6. 2008
    ..These data illustrate that SCV-07 may provide an easily administered alternative or supplemental treatment option for genital HSV-2 recurrent disease...
  100. ncbi Recurrent benign lymphocytic meningitis
    Marwan Shalabi
    Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Clin Infect Dis 43:1194-7. 2006
    ..This therapy is thought to be beneficial, although there is no controlled trial data to support efficacy and safety...
  101. ncbi Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial
    Jared M Baeten
    Department of Epidemiology, University of Washington, Seattle, Washington 98104 2499, USA
    J Infect Dis 189:1466-71. 2004
    ..Vitamin A supplementation is unlikely to decrease HSV shedding and infectivity...

Research Grants63

  1. Multilevel Targeted Therapeutics Using Surface Functionalized Nanoparticles encap
    JILL STEINBACH; Fiscal Year: 2012
    ..I expect this approach will improve current HSV-2 therapy and can be extended to multiple STD combinations, including elusive viruses such as HIV. ..
  2. Development of a Novel Vaccine Against Herpes Simplex Type 2
    DEBORAH SPECTOR; Fiscal Year: 2009
    ..S. population together with the medical and psychological impacts of the disease make HSV-2 an important candidate for the development of an effective vaccine that can prevent infection or disease. ..
  3. CHARACTERIZATION OF A NOVEL HOST PATHWAY THAT REGULATES CHLAMYDIAL DEVELOPMENT
    Robert V Schoborg; Fiscal Year: 2013
    ....
  4. Can Sexually Transmitted Pathogens Impact the Efficacy of HIV-1 Microbicides?
    SUSANA NOEMI ASIN; Fiscal Year: 2013
    ....
  5. Mechanisms of CD8+ T cell Immune surveillance in human genital skin and mucosa af
    Jia Zhu; Fiscal Year: 2012
    ....
  6. Clinical Epidemiology and Pathogenesis of Asymptomatic HSV
    Anna Wald; Fiscal Year: 2013
    ....
  7. Blocking immune evasion as a novel immunotherapy for recurrent HSV-2 infection
    HARVEY MICHAEL FRIEDMAN; Fiscal Year: 2013
    ....
  8. The gender specific prevalence of multiple strain genital HSV-2 infection
    Anna Wald; Fiscal Year: 2013
    ..multiple strain infection. Together, these data will clarify the relationship between gender an HSV-2 susceptibility and provide a benchmark for the likely efficacy of HSV-2 vaccines. ..
  9. Novel Methylenecyclopropane Analogues as Anti-Human Herpesvirus 6 and 8 Agents
    Terry L Bowlin; Fiscal Year: 2013
    ....
  10. Heterogeneity in Cytokine Responses to HIV-1 Infection
    Jianming Tang; Fiscal Year: 2011
    ..Tang to pursue targeted experimental studies and substantially strengthen a collaborative research program that focuses on infection and immunity in immunocompromised hosts. ..
  11. Bioresponsive Combination Microbicide Delivery System for HIV and HSV
    PATRICK FRANKLIN contact KISER; Fiscal Year: 2010
    ..Such experiments, planned for years 3-5 will determine dose response, dose frequency and dose duration that provide maximum protection against HIV transmission. ..
  12. Therapeutic immunization to impact HSV-2 latency and associated pathogenesis
    Nigel Bourne; Fiscal Year: 2013
    ..Aim 4 will develop novel vaccine constructs designed to increase cell-mediated immune responses to immunization and to more effectively interfere with HSV-2 latency and reactivation. ..
  13. School Support as Structural HIV Prevention for Adolescent Orphans in Kenya
    Hyunsan Cho; Fiscal Year: 2013
    ..Analyses will test posited mediators and gender moderation in causal pathways and program effects. Cost effectiveness analyses will add much needed policy-relevant information. ..
  14. Innate Resistance to Mucosal HSV Infection in Humans
    Christine M Posavad; Fiscal Year: 2010
    ..The goal of this proposal is to determine the mechanism of this apparent resistance in order to develop strategies to prevent genital herpes. ..
  15. A low-cost point-of-care diagnostic test for simultaneous HIV-1 & STI
    SAMUEL SIA; Fiscal Year: 2009
    ..This proposal aims to develop a rapid point-of-care (POC) test that simultaneously diagnoses HIV-1 and two sexually transmitted infections (STI's), syphilis and genital herpes. ..
  16. Engineering antiviral innate immunity for safe and effective microbicides
    Hong Shen; Fiscal Year: 2013
    ..This application will enable the translation of TLR-based antiviral innate immunity to effective and safe microbicides. ..
  17. T Cell Immunity to HSV-2 in Immune Seronegative Subjects
    Christine M Posavad; Fiscal Year: 2013
    ..The goal of this proposal is to characterize the immune response to herpes in these subjects in order to develop vaccine strategies to prevent herpes. ..
  18. Induction of Apoptosis in T cells by Herpes Simplex Virus Type 2
    Jin Young Han; Fiscal Year: 2010
    ..This work has potential applicability in developing novel therapies to reduce public health consequences from virus reactivation in genital and neonatal infections. ..
  19. Interaction between HSV-2 and the vaginal microbiome in the female genital tract
    CHRISTINE MICHELLE JOHNSTON; Fiscal Year: 2012
    ..Ultimately, this proposal will provide us with knowledge to better promote women's reproductive health. ..
  20. Micro-nano Platforms for HSV Vaccine
    Deepak Shukla; Fiscal Year: 2013
    ..Overall, we expect to prove the vaccine efficacy of a new virostatic platform, which will have path defining implications for protection against HSV-2 and many additional viral diseases. ..
  21. Genetics and Functions of HSV Membrane Fusion Proteins
    KONSTANTIN KOUSOULAS; Fiscal Year: 2009
    ....
  22. Inhibition of Herpes Simplex Virus Type 2 by Tenofovir
    Nicholas J Van Wagoner; Fiscal Year: 2013
    ..There is need to identify new agents that effectively prevent and treat HSV-2, especially in HIV infected populations. In this grant, I will investigate Tenofovir's (TDF) anti-HSV-2 activity in vivo and in vitro. ..
  23. DRUG USE AND HIV RISK AMONG YOUTH
    Samuel Friedman; Fiscal Year: 1999
    ..These findings can help target interventions where they are most needed and develop strategies to prevent high-risk drug use, high-risk sex, and infection with HIV. ..
  24. HIGH RISK COHORTS IN KENYA; PROSTITUTES AND TRUCKDRIVERS
    Joan Kreiss; Fiscal Year: 1993
    ..In addition, it is anticipated that these cohorts will form the basis for future HIV vaccine trials in Kenya...
  25. Economic Opportunity for Zimbabwean Adolescent Orphans
    Philip Darney; Fiscal Year: 2007
    ..e., factors related to participant adherence, satisfaction, and understanding of the intervention mediate observed effects. ..
  26. Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission
    KAREN MARK; Fiscal Year: 2009
    ....
  27. HIV RISK REDUCTION THROUGH HSV-2 PREVENTION WITH N-9
    Nancy Padian; Fiscal Year: 2002
    ..By simply adding an additional tube of blood and a diagnostic test to an established phase III trial in Zimbabwe, the study being proposed here may answer these important questions. ..
  28. Vaccine-elicited genital and neuronal T cell responses
    Gregg Milligan; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  29. GLYCOSAMINOGLYCAN RECEPTORS FOR HSV-1 AND HSV-2
    Betsy Herold; Fiscal Year: 1999
    ....
  30. HSV-2 shedding: role of hormonal contraception and BV
    THOMAS CHERPES; Fiscal Year: 2009
    ..The effects of exogenous sex steroids on the capacity of HSV-specific T lymphocytes to inhibit HSV reactivation in sensory neurons and subsequent shedding on epithelial surfaces in a murine model. ..
  31. Herpes Simplex Immunotherapeutic Vaccine
    Sean Sullivan; Fiscal Year: 2009
    ..Aim 4. Based on results from Aims 1-3, plan and initiate non-clinical safety studies on a candidate pDNA HSV-2 immunotherapeutic vaccine and file an IND with the FDA. ..
  32. DNA vaccine effiicacy in Herpes Simplex Virus type 2
    JANE STRASSER; Fiscal Year: 2004
    ....
  33. INDUCTION OF CHLAMYDIAL PERSISTENCE BY HSV-2
    ROBERT SCHOBORG; Fiscal Year: 2005
    ..Additionally, novel mechanisms for induction of chlamydial persistence may be identified, thus increasing our understanding of chlamydial/host cell interactions. ..
  34. Impact of HSV-2 testing on asymptomatic college students
    Hayley Mark; Fiscal Year: 2005
    ..2. Compare psychological and behavioral responses of students who receive a positive test result for HSV-2 with those of students who receive a negative test result at recruitment and three months after receiving results. ..
  35. MICROBICIDES IN MODEL SYSTEMS
    Mary K Howett; Fiscal Year: 2003
    ..trachomatis in a porcine model will be established and microbicides tested in this system. ..
  36. MECHANISTIC APPROACHES TO HSV-2 INDUCED TRANSFORMATION
    Clinton Jones; Fiscal Year: 1992
    ....
  37. VACCINIA VECTORED HSV GENES IN PROTECTIVE IMMUNITY
    Laure Aurelian; Fiscal Year: 1991
    ....
  38. Response of Genital Tract HIV-1 to HAART: Role of HSV-2?
    Carolyn Wester; Fiscal Year: 2009
    ..Blood and genital tract specimens will be collected and analyzed at baseline and 6 months after HAART initiation. ..
  39. HERPESVIRUS EXPRESSION IN TRANSFORMATION AND LATENCY
    DENISE GALLOWAY; Fiscal Year: 1991
    ..The ability of selected HSV and CMV promoters to respond to glucocorticoids, hormones, etc will be examined as a basis to understand reactivation...
  40. Immune Correlates of HSV-2 Disease Severity
    David Koelle; Fiscal Year: 2001
    ..The data will also reveal the in vivo effects of HSVencoded immune evasion genes on the CD8 CTL response within the natural host. ..
  41. Use of Modified Lactobacilli to Block HSV Transmission
    CHIA HWA CHANG; Fiscal Year: 2003
    ....
  42. Treatment of Acute Hepatitis C in Injection Drug Users
    Anna Wald; Fiscal Year: 2005
    ..abstract_text> ..
  43. A Mucosal Vaccine for HSV-2
    REBECCA TIRABASSI; Fiscal Year: 2007
    ..The PHS publication, "Healthy People 2010", has set sexually transmitted diseases as a national priority with a goal to reduce the number of adults infected with human papilloma virus and HSV-2. [unreadable] [unreadable] [unreadable]..
  44. Intradermal vaccinia:T-cell specificity and skin homing
    David Koelle; Fiscal Year: 2005
    ..2) Measure E-selectin binding by vaccinia-specific CD8 cells, and 2.3) Compare CLA and E-selectin binding by vaccinia-specific T-cells in recent and distant vaccines. ..
  45. HSV Immunotherapeutic Vaccine
    David Koelle; Fiscal Year: 2005
    ....
  46. Immune Correlates of HSV-2 Disease Severity
    David Koelle; Fiscal Year: 2007
    ....
  47. Vaccinia: T-cell immunity and homing to skin
    David Koelle; Fiscal Year: 2009
    ..Our data will assist in evaluating the immunogenicity of these constructs. ..
  48. Immunogenicity of Subunit Vaccine Delivered by FcRn
    Xiaoping Zhu; Fiscal Year: 2007
    ..that infect at or invade across mucosal surfaces. [unreadable] [unreadable] [unreadable]..
  49. Neuroprotection and ERK activation by HSV-2 gene ICP10PK
    Laure Aurelian; Fiscal Year: 2007
    ..The studies will provide significant information required for the development of ICP10PK based therapies for the treatment of acute and chronic neurodegenerative diseases that are associated with apoptosis. ..
  50. HUMAN PAPILLOMAVIRUSES IN CERVICAL CANCER
    JOHN KREIDER; Fiscal Year: 1990
    ..Some of these agents include benzopyrene, n-methylnitrosamine, estrogens, and herpes simplex virus type 2...
  51. Immunization to Reduce Genital and Neonatal Herpes
    Nigel Bourne; Fiscal Year: 2009
    ..These study designs may become standard for preclinical evaluation of HSV vaccines. ..
  52. MOLECULAR STUDIES OF ERYTHEMA MULTIFORME
    Laure Aurelian; Fiscal Year: 2004
    ..They will also generate clinically relevant information for the diagnosis and management of HAEM patients as differentiated from those with EM caused by other pathogens or by drug sensitivity. ..
  53. Morpholino Antisense Drugs for Hepatitis C Virus
    Nigel Bourne; Fiscal Year: 2004
    ..The proposed research, if successful, would lead to a application for Phase II funding to bring the use of PMOs into the HCV drug market and provide a well-tolerated, inexpensive alternative to current HCV treatments. ..
  54. HSV-SERONEGATIVE PERSONS WITH AQUIRED IMMUNITY TO HSV
    Christine Posavad; Fiscal Year: 2002
    ..abstract_text> ..
  55. Acylovir to prevent HIV acquisition in HSV-2+persons
    Connie Celum; Fiscal Year: 2004
    ..abstract_text> ..
  56. Novel inhibitors of the replication of poxviruses
    Johan Neyts; Fiscal Year: 2004
    ..The final goal of this application is to advance a compound for the treatment of (systemic or cutaneous) poxvirus infections to the initial stages of development, i.e., selecting an IND candidate. ..
  57. Human Resistance to Herpes Simplex Virus Infections
    Christine Posavad; Fiscal Year: 2005
    ..The data generated will be relevant to designing and evaluating strategies for HSV-2 preventative vaccines and immunotherapy. ..
  58. Acyclovir to Prevent HIV Acquisition in HSV-2+ Persons
    Connie Celum; Fiscal Year: 2007
    ..Given high HSV-2 infection rates globally in persons at risk for HIV, this approach could have great public health impact by providing a safe, acceptable and cost-effective method to reduce HIV susceptibility. [unreadable] [unreadable]..
  59. STDS AND HETEROSEXUAL 'BRIDGING' AMONG MEN WHO HAVE SEX
    Connie Celum; Fiscal Year: 2006
    ....
  60. The Role of CXCL9 in Genital HSV-2 Infection
    Daniel Carr; Fiscal Year: 2009
    ..g., vaccine or gene transfer) to reduce the incidence of infection or reduce the capacity of latent virus to reactivate. ..
  61. NEUROIMMUNOLOGY OF AED IN OCULAR HSV-1 INFECTION
    Daniel Carr; Fiscal Year: 2001
    ..abstract_text> ..
  62. Male Circumcision Trial for HIV Prevention, Rakai-Uganda
    Ronald Gray; Fiscal Year: 2006
    ..Control arm men will be offered circumcision as a service in Years 4-5, contingent on DSMB approval. ..